Abstract: Provided is a crystalline polymorphic form A of 15?-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteristic diffraction peaks of the crystalline polymorphic form A of 15?-hydroxy-osaterone acetate appear at diffraction angles 2? of 9.6°±0.2°, 17.1°±0.2°, and 20.2°±0.2°. The crystalline polymorphic form A has a melting point of 280 to 283° C. and is a prism crystal.

Abstract: Provided is a crystalline polymorphic form A of 15?-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteristic diffraction peaks of the crystalline polymorphic form A of 15?-hydroxy-osaterone acetate appear at diffraction angles 2? of 9.6°±0.2°, 17.1°±0.2°, and 20.2°±0.2°. The crystalline polymorphic form A has a melting point of 280 to 283° C. and is a prism crystal.

Abstract: A decoration part includes a base member having a front-side surface and an outer peripheral end portion, a skin covering the front-side surface of the base member, and a holding member mounted to the front-side surface of the base member and arranged on a rear-surface side of the skin. The skin has a stitch line formed with a thread, and a part of the stitch line is arranged in the outer peripheral end portion. The holding member holds the thread with which the skin and the holding member are sewed and has a linear shape extending along the stitch line. The holding member has a mount portion mounted to a holding member mount portion of the base member and a stitch portion that is sewed with the thread. The holding member has the stitch portion closer to an outer peripheral end of the base member than the mount portion.

Abstract: A decoration part includes a base member having a front-side surface and an outer peripheral end portion, a skin covering the front-side surface of the base member, and a holding member mounted to the front-side surface of the base member and arranged on a rear-surface side of the skin. The skin has a stitch line formed with a thread, and a part of the stitch line is arranged in the outer peripheral end portion. The holding member holds the thread with which the skin and the holding member are sewed and has a linear shape extending along the stitch line. The holding member has a mount portion mounted to a holding member mount portion of the base member and a stitch portion that is sewed with the thread. The holding member has the stitch portion closer to an outer peripheral end of the base member than the mount portion.

Abstract: The invention provides a crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid (which has the chemical structure shown below) and a mixed crystal comprising such a crystal. The invention also provides methods of producing such crystals, pharmaceutical compositions comprising such crystals, and methods of modulating phosphodiesterase-9 activity and treating disorders such as overactive bladder syndrome by administration of an effective amount of the crystals.

Abstract: The invention provides a crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid (which has the chemical structure shown below) and a mixed crystal comprising such a crystal. The invention also provides methods of producing such crystals, pharmaceutical compositions comprising such crystals, and methods of modulating phosphodiesterase-9 activity and treating disorders such as overactive bladder syndrome by administration of an effective amount of the crystals.

Abstract: The invention provides a crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid (which has the chemical structure shown below) and a mixed crystal comprising such a crystal. The invention also provides methods of producing such crystals, pharmaceutical compositions comprising such crystals, and methods of modulating phosphodiesterase-9 activity and treating disorders such as overactive bladder syndrome by administration of an effective amount of the crystals.

Abstract: Disclosed is a method for screening a compound having an activity that selectively modulates an androgen receptor, comprising a step of measuring the mRNA expression level of prostate-specific antigen or the production level of prostate-specific antigen in prostate cancer cells by contacting a test substance with the prostate cancer cells, and a step of measuring the mRNA expression level of uncoupling protein 1 or the production level of uncoupling protein 1 in adipocytes by contacting a test substance with the adipocytes. Additionally disclosed is a selective androgen receptor modulator, comprising as an active ingredient thereof a compound represented by any of structural formulas (I) to (III), and a composition for preventing or treating a lifestyle-related disease, comprising as an active ingredient thereof said selective androgen receptor modulator.

Abstract: An attachment structure for a clip including a mounting member, a retaining hole formed in the mounting member, and a rib. An elastic retaining piece of the clip, while elastically deformed, is inserted into the retaining hole from an outer side of the mounting member toward an inner side to be retained therein. The rib is disposed around the retaining hole and is formed integrally with the mounting member. The rib includes a first rib formed on the inner side of the mounting member and a second rib formed outside, and concentric to, the first rib. The first rib has a thickness such that a clip press-contacting piece abuts the outer side of the mounting member when the elastic retaining piece is inserted in the retaining hole and retained on the rib, and the second rib has a thickness larger than the thickness of the first rib.

Abstract: Crystals are obtained by heating an aqueous suspension of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid. Novel crystals are obtained by adjusting the heating temperature and/or duration.

Abstract: Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the level of expression of mRNA for a prostate-specific antigen or the level of production of the prostate-specific antigen in the prostate cancer cell; and contacting the substance with an adipocyte and measuring the level of expression of mRNA for uncoupling protein-1 or the level of production of uncoupling protein-1 in the adipocyte. Also disclosed is a selective androgen receptor modulator comprising a compound represented by any one formula selected from the structural formulae (I) to (III) as an active ingredient. Further disclosed is a composition for preventing or treating lifestyle-related diseases, which comprises the selective androgen receptor modulator.

Abstract: To provide an attachment structure of a clip in which merely by adding a simple construction to a wall body of a mounting member, deformation of that portion around a retaining hole is eliminated, and the clip can be attached in a stable condition. In the attachment structure of the clip (1) which is attached by inserting part thereof into the retaining hole (11) formed in the wall body (10) of the mounting member and by retaining it therein, and in the attachment structure of the clip including elastic retaining pieces (4, 4) which are elastically deformed and inserted into the retaining hole (11) to be retained in the retaining hole (11), a first rib (12) is formed integrally on the wall body (10) and is disposed around the retaining hole (11) in the wall body (10), and a second rib (13) is further formed on the wall body (10) in surrounding relation to the periphery of the elastic retaining pieces (4, 4).

Abstract: This invention provides cyclicamino-phenyl sulfamate derivatives represented by a formula wherein each of R1 and R2 stands for hydrogen or lower alkyl; each of R3 and R4 stands for hydrogen, halogen, cyano or the like; A stands for nitrogen or CH; B stands for CH2, SO2, CO, optionally substituted phenyl or the like; and R5 stands for alkyl, phenyl, amino or the like, or salts thereof which exhibit excellent steroid sulfatase inhibitory activity and are useful for prevention or treatment of diseases associated with steroids such as estrogen, androgen and the like.

Abstract: This invention provides cyclicamino-phenyl sulfamate derivatives represented by a formula wherein each of R1 and R2 stands for hydrogen or lower alkyl; each of R3 and R4 stands for hydrogen, halogen, cyano or the like; A stands for nitrogen or CH; B stands for CH2, SO2, CO, optionally substituted phenyl or the like; and R5 stands for alkyl, phenyl, amino or the like, or salts thereof which exhibit excellent steroid sulfatase inhibitory activity and are useful for prevention or treatment of diseases associated with steroids such as estrogen, androgen and the like.

Abstract: Phenyl sulfamate derivatives represented by the following formula or salts thereof have a powerful inhibitory effect on steroid sulfatase and are hence useful for the prophylaxis or treatment of diseases associated with steroids such as estrogens, such as breast cancer, corpus uteri cancer, endometrial hyperplasia, infertility, endometriosis, adenomyosis uteri, autoimmune disease, dementia or Alzheimer's disease. wherein R1 and R2 each independently represent a hydrogen atom or a lower alkyl group; R3 represents a hydrogen atom, a halogen atom, a lower alkyl group, —OSO2NR1R2, a lower alkanoylamino group, a nitro group or a cyano group; and A represents a substituted or unsubstituted phenyl group, a group of the formula —X—NR4R5, or the like.

Abstract: An exhaust manifold comprising a plurality of exhaust pipes and a merging portion applies exhaust gas from each cylinder uniformly to an oxygen sensor in a merging portion at low speed thereby improving the durability of the oxygen sensor. A downstream forward end of each exhaust pipe of the exhaust manifold, when connected to an inlet wall of a merging case having the oxygen sensor mounted on a side thereof, is formed in the shape of a bell mouth for leading the exhaust gas to the oxygen sensor. Each exhaust pipe is fixedly welded to the merging case at a position upstream of the forward end of the bell mouth. An angle formed by lines perpendicular to tangential lines at starting and ending points of a curved portion of the bell mouth at the forward end of the exhaust pipe is set in the range of 45.degree. to 75.degree.. As a result, the bell mouth spreads over the whole interior of the merging case and reduces a flow rate of the exhaust gas, and part of the exhaust gas flows toward the oxygen sensor.

Abstract: In a rear engined or mid engined type of automotive vehicle in which a liquid cooled internal combustion engine is mounted at least partly behind a passenger compartment, and a radiator for cooling the cooling fluid of the engine is mounted in front of the passenger compartment, with a mechanism being provided for conducting flow of cooling fluid between the cooling fluid jacket of the engine and the radiator in both directions, a cooling system for lubricating oil of the engine includes a heat exchanger formed with a cooling fluid passage and a lubricating oil passage arranged to exchange heat therebetween to conduct respectively a flow of cooling fluid and a flow of lubricating oil from the internal combustion engine, wherein the cooling fluid passage of the heat exchanger is a part of the cooling fluid flow conducting mechanism, so as not to the heat exchanger without substantially increasing the flow resistance of the cooling fluid flow conducting mechanism.